This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Lean, M. Search for Related Content Social Bookmarking                         What's this?

Is there a metabolic rationale to support a weight loss programme to prevent diabetes?

Department of Human Nutrition, University of Glasgow, Glasgow Royal Infirmary, G31 2ER, Scotland, lean{at}clinmed.gla.ac.uk

It is well established that the incidences of type 2 diabetes and impaired glucose tolerance are very low at ideal body weight (body mass index [BMI] 21—22 kg/m²) but increases with increasing body fat and BMI. Adipose tissue is an active endocrine organ which secretes many hormones involved in the regulation of body weight and appetite, including leptin and tumour necrosis factor-alpha, which are related to diabetes development. Weight loss is an important goal within the overall management of diabetes, and recent intervention trials have established that the benefits of weight loss may extend to the prevention of diabetes itself. Weight loss associated with diet and exercise in the DPP and the FDPS, by the anti-obesity drug orlistat in the XENDOS trial, and by gastric surgery in the SOS study all significantly reduced the incidence of diabetes compared with controls. The prevention or reversal of obesity is therefore an increasingly important therapeutic target in the prevention of type 2 diabetes.

Key Words: type 2 diabetes • obesity • diet • exercise • appetite • diabetes prevention.

References

• Pi-Sunyer FX Weight and non-insulin-dependent diabetes mellitus. Am J Clin Nutr 1996;63(suppl 3):426S-429S.[Medline] [Order article via Infotrieve]
• Fuchtenbusch M., Standl E., Schatz H. Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2000;108:151-63.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• United Kingdom Prospective Diabetes Study (UKPDS) 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995;310:83-8.[Abstract/Free Full Text]
• Colditz GA, Willett WC, Rotnitzky A., Manson JE Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995; 122:481-6.[Abstract/Free Full Text]
• Lindahl B., Weinehall L., Asplund K., Hallmans G. Screening for impaired glucose tolerance. Results from a population-based study in 21,057 individuals. Diabetes Care 1999;22:1988-92.[Abstract/Free Full Text]
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• American Diabetes Association. Nutrition recommendations and principles for people with diabetes mellitus (Position Statement). Diabetes Care 2001;24:S44-S47.
• European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabetic Medicine 1999;16:716-30.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Lean ME Obesity - what are the current treatment options? Exp Clin Endocrinol Diabetes 1998;106(suppl 2):S22-S26.[Web of Science][Medline] [Order article via Infotrieve]
• Goldstein DJ Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992;16:397-415.[Web of Science][Medline] [Order article via Infotrieve]
• Lean MEJ, Powrie JK, Anderson AS, Garthwaite PH Obesity, weight loss and prognosis in type 2 diabetes. Diabetic Med 1990;7:228-33.[Web of Science][Medline] [Order article via Infotrieve]
• Williamson DF, Pamuk E., Thun M., Flanders D., Byers T., Heath C. Prospective study of intentional weight loss and mortality in overweight white men aged 40-64 years. Am J Epidemiol 1999;149:491-503.[Abstract/Free Full Text]
• Ravussin E., Swinburn A. Insulin resistance is a result, not a cause of obesity. Socratic debate: the pro side. Progress in Obesity Research. Eds: A Angel, H Anderson, C Bouchard, L Leiter and R Mendelson, Chapter 23 173-8 ( 1996).
• Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.[Abstract/Free Full Text]
• Tuomilehto J., Lindstrom J., Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.[Abstract/Free Full Text]
• Sjöström CD, Peltonen M., Wedel H., Sjostrom L. Differentiated long-term effects of intentional weight loss on diabetes and hypertension. Hypertension 2000;36:20-5.[Abstract/Free Full Text]
• Mora S., Pessin JE An adipocentric view of signaling and intracellular trafficking. Diabetes Metab Res Rev 2002;18:345-56.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Halle M., Berg A., Northoff H., Keul J. Importance of TNF-alpha and leptin in obesity and insulin resistance: a hypothesis on the impact of physical exercise. Exerc Immunol Rev 1998;4:77-94.[Web of Science][Medline] [Order article via Infotrieve]
• Lahlou N., Clement K., Carel JC et al. Soluble leptin receptor in serum of subjects with complete resistance to leptin: relation to fat mass. Diabetes 2000;49:1347-52.[Abstract]
• Tsofliou F., Pitsiladis Y., Malkova D., Wallace M., Lean MEJ. Moderate physical activity permits acute coupling between leptin and appetite-satiety measures in obese women. IJO 2003 (in press).
• Jequier E. Leptin signaling, adiposity, and energy balance.Ann N Y Acad Sci 2002;967:379-88.[Web of Science][Medline] [Order article via Infotrieve]
• Chu NF, Stampfer MJ, Spiegelman D. et al. Dietary and lifestyle factors in relation to plasma leptin concentrations among normal weight and overweight men. Int J Obes Relat Metab Disord 2001;25:106-14.and[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Hotamisligil GS, Spiegelman BM Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 1994;43:1271-8.[Abstract]
• Bullo-Bonet M., Garcia-Lorda P., Lopez-Soriano FJ et al. Tumour necrosis factor, a key role in obesity? FEBS Lett 1999;451:215-19.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Way JM, Gorgun CZ, Tong Q. et al. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 2001;276:25651-3.[Abstract/Free Full Text]
• Hegele RA, Kraw ME, Ban MR et al. Elevated Serum C-Reactive Protein and Free Fatty Acids Among Nondiabetic Carriers of Missense Mutations in the Gene Encoding Lamin A/C (LMNA) With Partial Lipodystrophy. Arterioscler Thromb Vasc Biol 2003;23:111-16.[Abstract/Free Full Text]
• Adamczak M., Wiecedilicek A., Funahashi T. et al. Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 2003;16:72-5.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Ukkola O., Santaniemi M. Adiponectin: a link between excess adiposity and associated comorbidities? J Mol Med 2002;80:696-702.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Lean MEJ, Powrie JK, Anderson AS, Garthwaite PH Obesity, weight loss and prognosis in type 2 diabetes. Diabetic Medicine 1990;7:228-33.[Web of Science][Medline] [Order article via Infotrieve]
• Astrup A., Buemann B., Flint A., Raben A. Low-fat diets and energy balance: how does the evidence stand in 2002? Proc Nutr Soc 2002; 61:299-309.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Kornegay CJ, Vasilakis-Scaramozza C., Jick H. Incident diabetes associated with antipsychotic use in the United Kingdom general practice research database. J Clin Psychiatry 2002;63:758-62.[Web of Science][Medline] [Order article via Infotrieve]
• Lindenmayer JP, Nathan AM, Smith RC Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatry 2001;62(suppl 23):30-8.[Web of Science][Medline] [Order article via Infotrieve]
• Lean MEJ, Pajonk FG Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes. Diabetes Care 2003 (in press).

The British Journal of Diabetes & Vascular Disease, Vol. 3, No. 1 suppl, S12-S17 (2003)
DOI: 10.1177/14746514030030010401


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Lean, M. Search for Related Content Social Bookmarking                         What's this?